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OBJECTIVE We sought to study the functional, clinical and prognostic implications of marked repolar-
ization abnormalities (MRA) sometimes seen in athletes’ electrocardiograms (ECGs).
BACKGROUND The clinical meaning of ECG MRA in athletes is unknown. No relationship has been drawn
between either training intensity or any particular type of sport and MRA. Athletes are
usually symptom free and do not show any decrease in their physical performance. It is as yet
unclear whether MRA may have a negative effect on the performance of such athletes in
competitive sports.
METHODS We studied 26 athletes with MRA (negative T waves $2 mm in three or more ECG leads
at rest). No athletes presented clinical symptoms of cardiac disease or decrease in their
physical performance. Clinical and physical examinations, ECG at rest, exercise test and
echocardiographic and antimyosin studies were performed in all athletes. Rest/exercise
myocardial perfusion single-photon emission computed tomography studies were performed
in 17 athletes. The follow-up ranged from 4 to 20 years (mean 6.7 years).
RESULTS Four athletes were excluded due to hypertrophic cardiomyopathy. Echocardiographic studies
showed right and left normal ventricular dimensions for highly conditioned athletes. In the
exercise test, heart rate was 166 6 12.4 beats/min, and exercise tolerance was 15.2 6 2.7
metabolic equivalents of the task. All athletes had ECG at rest simulating myocardial
ischemia or “pseudoischemia” with a tendency to normalize during exercise. Myocardial
perfusion studies were normal in the studied athletes. Antimyosin studies showed mild and
diffuse myocardial radiotracer uptake in 15 athletes (68%). No adverse clinical events were
observed in the follow-up.
CONCLUSIONS These results suggest that MRA have no clinical or pathological implications in athletes and
should, therefore, not preclude physical training or participation in sporting events. (J Am
Coll Cardiol 2000;36:1310–6) © 2000 by the American College of Cardiology
Physical training with dynamic exercise predominance pro-
duces changes both in heart structure and in the electrocar-
diogram (ECG). The most common changes in the struc-
ture of the heart are an increase in ventricular wall thickness
and the diameter of the left ventricle (LV), both evidenced
in echocardiographic studies. In the ECG, the most fre-
quent changes are sinus bradycardia, first degree heart block,
second degree Mobitz I (Wenckeback) and repolarization
alterations. Sinus bradycardia is almost constant and can be
below 30 beats per minute, especially during the night.
These ECG changes are more frequent in trained athletes
than they are in sedentary people (1–6).
Changes in ventricular repolarization are normally slight.
Marked repolarization abnormalities (MRA) are not com-
mon and suggest the presence of heart disease (Fig. 1). They
do not bear any apparent relation to training intensity or any
particular type of sport. Athletes are generally symptom-free
and do not show any decrease in their physical performance.
The purpose of this study was to assess the clinical
significance and prognosis of changes in ventricular repo-
larization in athletes with an ECG showing MRA. For this
purpose, we studied athletes with MRA by means of
echocardiography, exercise test, rest/exercise myocardial
perfusion single-photon emission computed tomography
and antimyosin studies.
METHODS
Subjects. We studied 26 male athletes (10 runners, 7 soccer
players, 2 waterpolo players, 2 pentathlon athletes, 2 bas-
ketball players, 1 swimmer, 1 cyclist and 1 triathlon athlete)
with a mean age of 29 6 11 years and a mean body surface
area of 1.74 6 1.5 m2. Two athletes were at international
competition level (one had participated three times in the
Olympic Games and the other once), and the remaining
athletes competed at a national level. All athletes showed
MRA in rest ECG. Marked repolarization abnormalities
were considered when negative T waves $2 mm were
present in three or more rest ECG leads. All athletes
included in the study were examined in the “Residencia
Blume,” a sports medicine cardiology reference center in
Barcelona, Spain. Athletes are referred from eight other
local sports medicine centers that monitor a total of 3,500
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athletes (from 25 different Olympic events) per year. Clin-
ical and physical examinations, echocardiographic studies,
exercise tests and antimyosin studies were carried out in all
cases. Rest/exercise myocardial perfusion studies were per-
formed in 17 athletes. The follow-up was between 4 and 20
years (mean 6.7 years). All athletes were informed about
study characteristics, including the use of radiotracers, and
all gave their written informed consent. The protocol was
approved by the Institutional Ethical Committee of the
Hospital de Sant Pau of Barcelona.
Echocardiographic study. Echocardiographic studies were
performed using a Vingmed Sonotron ultrasonograph CFM
700 with a 3.0-MHz transducer and were evaluated by three
independent observers. Echocardiograms were performed in
the semirecumbent and left lateral positions in accordance
with the American Society of Echocardiography Recom-
mendations (7). Left ventricular diastolic thickness of intra-
ventricular septum and posterior free wall, and diastolic and
systolic internal dimensions of right and LV cavities, were
evaluated in accordance with standard M-mode echocardio-
graphic criteria (8). In all subjects two-dimensional images
were performed to assist in interpretation of data.
The LV mass was calculated using the American Society
of Echocardiography’s recommended formula (7–9): LV
mass (g) 5 1.04 ([LV internal diameter 1 septum thick-
ness 1 posterior wall thickness]3—[LV internal diame-
ter3])—13.6. The LV mass index was calculated from the
relation between LV mass and body surface area.
Exercise test. The exercise test was performed using the
Bruce protocol on a treadmill (Quinton 500 System).
Athletes were encouraged to continue the exercise until
exhaustion. Seven athletes stopped the exercise because of
leg fatigue. Twelve ECG leads were recorded at rest, during
the exercise and 10 min after recovery. Blood pressure was
registered at rest and every 3 min during the exercise.
Rest/exercise myocardial perfusion study. The rest/
exercise perfusion studies were performed using a two-day
protocol. Seven-hundred and forty MBq of 99m technetium
(Tc)-tetrofosmin (Myoview, Nycomed Amersham) was in-
travenously administered twice, once at rest and again at the
peak of maximum effort during the exercise test. Athletes
were asked to drink a glass of whole milk to accelerate
hepatobiliary clearance. Single-photon emission computed
tomography studies were performed using a rotating gam-
macamera (Elscint, Helix HR) with a low-energy, high-
resolution collimator. A 10% window was centered over the
140 keV 99mTc photopeak. Sixty projections of 20 s each
were acquired in step-and-shoot mode over a 180° circular
orbit, from the 45° right anterior oblique to the 45° left
posterior oblique views, with a zoom factor of 1.4 and a
64 3 64 byte matrix. Series of 6.2 mm-thick transverse
slices were reconstructed using filtered backprojection with
a ramp filter and smoothed with a Butterworth filter (cut-off
frequency 0.4 cycles/pixel, power 16 for 99mTc-tetrofosmin
studies). The data were reconstructed in short axis, hori-
zontal long axis and vertical long axis views, and neither
scatter nor attenuation correction was applied. The slice set




LV 5 left ventricle, left ventricular
MRA 5 marked repolarization abnormalities
Tc 5 technetium
Figure 1. Electrocardiogram of athlete 10 who participated in the Olympic Games in Los Angeles. This electrocardiogram, performed 12 years later when
training level was significantly lower, continues to show marked repolarization abnormalities.
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Antimyosin study. The antimyosin studies were per-
formed within two weeks of echocardiographic studies. A
dose of 0.5 mg of R11-D10-Fab-dietilentriamine-
pentaacetic (Centocor Europe, Leiden, the Netherlands)
labelled with 74 MBq of 111indium (In) was administered
by slow intravenous injection. Planar anterior projection
scans of the thorax were acquired 48 h later using a camera
with a large view field collimator linked to a computer
(Siemens Orbiter, Microdelta) with a medium energy
collimator. A 20% window was centered on both energy
photopeaks of 111In, and the acquisition time was 10 min.
Scans were stored in 128 3 128 frames for subsequent
analysis. A semiquantitative method was applied to
evaluate the intensity of the myocardial antimyosin up-
take, consisting of drawing regions of interest over the
heart and lungs on the anterior view of the thorax (10). A
heart-to-lung ratio was obtained by dividing the average
counts per pixel of the heart by the average counts per
pixel of the lungs. A cut-off point .1.55 (normal value 1
2 standard deviations) was used to define abnormal
studies (10).
Statistical analysis. Results are expressed as mean 6 stan-
dard deviation of mean. A two-tail Pearson’s linear corre-
lation test was used to assess the correlation between
variables. Correlation was considered present when p ,
0.05.
RESULTS
Echocardiography detected signs of hypertrophic cardiomy-
opathy in four athletes, who were excluded from the study.
Clinical and physical examinations were normal in the
remaining 22 athletes, none of whom presented adverse
clinical events or a decrease in physical performance during
the follow-up.
Echocardiographic study. Right and left ventricular di-
mensions were normal for highly trained athletes. Left
ventricular diastolic diameter was 54.2 6 4.6 mm (range
60.5 to 40.9), and systolic diameter was 33.3 6 4.6 mm
(range 40.1 to 24); thickness of intraventricular septum was
10.5 6 1.4 mm (range 13.1 to 7.8), and thickness of
posterior wall was 9.4 6 1.2 mm (range 7 to 11.2); LV mass
index was 148 6 39.2 g/m2 (range 220 to 82) (Table 1). No
signs of right ventricular abnormalities were seen. Aortic
root and left atria dimensions were within normal limits,
and systolic and diastolic functions were normal in all
athletes.
Exercise test. Heart rate at exercise was 166 6 12.4
beats/min (range 141 to 189), and physical fitness, evaluated
in metabolic equivalent of the task, was 15.2 6 2.7 (range
10 to 20). The increase in blood pressure during the test was
normal in all cases. Electrocardiogram tracer at rest simu-
lated myocardial ischemia or “pseudoischemia” and tended
to normalize during the exercise in all athletes; T wave
Table 1. Results of Echocardiographic and Antimyosin Studies and ECG Pattern (Between Parenthesis ECG Leads) in Athletes
With MRA
n (age) Sport BSA MWTs MWTp LVD LVS MI HRL ST level T wave
1 (25) B 2.28 13 10 61 40 159 1.57 25 (V4)
2 (30) SC 1.71 8 8 47 27 82 1.67 14 (V3) 28 (V4)
3 (18) C 1.59 12 10 57 39 164 1.88 14 (V2)
4 (19) S 1.74 13 11 54 37 184 1.65 23 (VF)
5 (48) SC 1.64 10 8 58 36 109 1.52 27 (V4)
6 (24) R 1.65 9 9 55 32 140 1.72 13 (V2) 25 (V3)
7 (19) SC 1.83 11 9 49 33 114 1.68 11 (V3) 24 (V2)
8 (32) SC 1.70 11 11 46 24 132 1.42 12 (V3) 27 (V4)
9 (18) WP 1.84 10 8 54 36 214 1.61 12 (III) 22 (III)
10 (39) R 1.68 11 11 50 26 147 1.88 14 (V3) 220 (V5)
11 (18) WP 1.77 10 8 54 32 121 1.38 13 (V3) 27 (V4)
12 (39) R 1.84 8 7 57 31 147 1.51 12 (V2) 25 (V1)
13 (36) R 1.60 11 11 54 38 194 1.87 13 (V2) 28 (V1)
14 (58) T 1.66 11 10 55 34 104 1.56 12 (V2) 24 (V1)
15 (38) R 1.70 12 10 53 35 167 1.47 13 (V2) 24 (V1)
16 (39) R 1.63 9 9 59 40 159 1.62 13 (V3) 211 (V3)
17 (34) SC 1.71 12 9 63 36 156 1.74 12 (V4) 218 (V4)
18 (20) P 1.64 10 10 48 31 101 1.57 14 (V2) 25 (V3)
19 (18) P 1.69 10 8 59 36 121 1.54 13 (V2) 27 (V3)
20 (23) SC 1.92 10 9 50 29 109 1.50 12 (V2) 213 (V5)
21 (28) R 1.85 12 9 52 27 211 1.60 12 (V2) 27 (V4)
22 (18) R 1.70 10 10 59 33 220 1.63 25 (V4)
Mean
6 SD
1.74 6 0.15 11 6 1.4 9 6 1.2 54 6 4.6 33 6 4.6 148 6 39 1.61 6 0.13 12.30 6 1.3 26.87 6 4.5
B 5 basketball player; BSA 5 body surface area (m2); C 5 cyclist; HLR 5 heart-to-lung ratio (myocardial antimyosin uptake); LVD 5 left ventricular end-diastolic diameter
(mm); LVS 5 left ventricular end-systolic diameter (mm); MI 5 mass index (g/m2); MRA 5 marked repolarization abnormalities; MWTp 5 maximal posterior wall thickness
(mm); MWTs 5 maximal septal wall thickness (mm); P 5 pentathlon athlete; R 5 runner; S 5 swimmer; SC 5 soccer player; SD 5 standard deviation; T 5 triathlon athlete;
WP 5 waterpolo player.
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voltage and isoeletric ST segment decreased (Fig. 2). Dur-
ing the recovery period, MRA reappeared in ECG tracer
within 8 min. No arrhythmias were recorded.
Rest/exercise myocardial perfusion study. The rest/
exercise myocardial distribution of 99mTc-tetrofosmin was
normal, and no images of ischemia were evidenced.
Antimyosin study. Heart-to-lung ratio was 1.61 6 0.13
(range 1.38 to 1.88) (Table 1). Fifteen athletes (68%) had a
heart-to-lung ratio .1.55, showing mild and diffuse myo-
cardial antimyosin uptake. No correlation between the
heart-to-lung ratio and the LV mass index or the maximal
wall thickness was found.
DISCUSSION
Physical training produces changes in the athlete’s cardiovas-
cular system, particularly in heart rate. Sinus bradycardia is the
most frequent change, and heart rate at rest can be below 30
beats per minute. Slight changes in ventricular repolarization
are also common, especially in early repolarization. These
changes are characterized by ST segment elevation $0.5 mm
in two consecutive leads and by J wave or terminal slurring of
R wave, most frequently in precordial leads. In the athlete’s
heart, these changes are related to modifications of the auto-
nomic nervous system and myocardial structure (8,11–16).
Figure 2. Upper: electrocardiogram with marked repolarization abnormalities at rest. Lower: exercise electrocardiogram of the same athlete showing a
decrease in the T wave voltage in V4 to V6 and a positive T wave in V2 to V3.
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Prevalence and significance of MRA. To our knowledge,
there are no data available to date in the scientific literature
about the prevalence of MRA in athletes. In Spain, the
prevalence of MRA in athletes is unknown, mainly because
strict medical controls are not usually required for regular
competition. Although MRA is infrequent, it is not a new
finding in sports cardiology. Marked repolarization abnor-
malities in ECG tracer suggest heart disease, but the
athletes are free of cardiac symptoms, and they show a
normal physical performance in relation to their training
level. Moreover, the presence of MRA is not associated with
top-ranking training, with prolonged training or with any
particular type of sport (16). It has been suggested that
MRA could be related to changes in the cardiac autonomic
nervous system. Previous studies in athletes with MRA did
not show significant differences in plasmatic levels of nor-
epinephrine and dopamine compared with a group of
athletes with normal ECG, and, moreover, heart disease
was also discarded by echocardiography, stress test and
201T1 perfusion studies (17,18). However, these studies do
not enable any definitive conclusions to be drawn about the
implication of the autonomic nervous system in MRA.
When MRA in ECG tracer suggest heart disease, it is
necessary to determine whether the athlete should continue
physical training. In most cases there is no family history of
sudden cardiac death or other heart diseases; symptoms at
rest and during exercise are absent, and performance level is
no different from athletes with normal ECG. An echocar-
diography is performed in these cases, and, if this is
pathologic, it is associated with apical cardiomyopathy (19).
For this reason, athletes with hypertrophic cardiomyopathy
were excluded from the study in order to avoid their possible
influence on the results. It is, therefore, surprising that 4 of
26 athletes (15%) had hypertrophic cardiomyopathy, and
this finding suggests the possibility that, although athletes
with MRA have no evidence of heart disease, they are not
strictly free of some cardiac disorder.
Risk factors and MRA. Risk factors associated with sud-
den cardiac death are youth, syncope, family history of
sudden death and ventricular tachycardia accompanied by
clinical and electrophysiologic findings (20). In our study
the exercise test was performed until physical exhaustion to
exclude ischemic heart disease, especially in older athletes.
In all tests the exercise ECG returned to normal, and the
MRA reappeared within 8 min of the recovery period; there
were no supraventricular or ventricular arrhythmias during
the exercise or in the recovery period. Physical performance,
evaluated in metabolic equivalents of the task, was at the
level of highly trained individuals in all cases. The rest/
exercise myocardial perfusion studies were normal, and
echocardiographic studies were compatible with highly
trained athletes, showing a thickness of interventricular
septum and posterior wall within physiological limits (21).
Finally, 15 athletes (68%) showed mild and diffuse myocar-
dial antimyosin uptake. Maron et al. (22) reported that
sudden cardiac death is more frequent during or after
exertion periods, suggesting the importance of hemody-
namic collapse as a trigger. Athletes with MRA did not
show any risk factor of sudden cardiac death, and the
behavior of the systolic blood pressure during exercise test
was also normal. There does not, therefore, appear to be any
reason to exclude athletes with MRA in ECG at rest from
training or competition.
In athletes with MRA and demonstrated heart disease, it
is easier to decide on future physical activity. Marked
repolarization abnormalities in the context of hypertrophic
cardiomyopathy are accompanied by pathological behavior
during exercise, coexisting with an abnormal increase in
blood pressure (23). The Brugada Syndrome (24), showing
ST segment elevation in the right precordial leads, could
lead to MRA, but in this study no athletes presented
evidence of right bundle branch block or ventricular tachy-
arrhythmias during the follow-up, thereby excluding this
syndrome as the cause of MRA. Right ventricular disease,
such as right ventricular dilation in arrhythmogenic right
ventricular dysplasia, was excluded by echocardiography,
where right ventricular dimensions were normal without
pathological findings in all athletes.
Controversial role of myocardial antimyosin study in
MRA. More difficult to explain is the mild and diffuse
myocardial antimyosin uptake evidenced in 68% of athletes.
Myocardial antimyosin uptake is specific for myocyte cell
membrane disruption or increased membrane permeability
(25,26), including small sarcolemmal breaches seen only
with high-resolution electromicroscopy (27). Myocardial
antimyosin studies are useful in the noninvasive detection of
myocardial cell damage in different clinical situations
(26,28–33). Mild and diffuse myocardial antimyosin uptake
in athletes with a very good performance suggests active
myocyte damage, without clinical or functional conse-
quences. Further studies are needed to understand the
meaning of myocardial antimyosin uptake in these subjects.
This finding could possibly be related to the high percentage
of hypertrophic cardiomyopathy found in this group of
athletes.
Follow-up and clinical implications. During the training
period, MRA show few changes, and these are always
related to modifications in the intensity of training. There-
fore, ECG alterations in ventricular repolarization do not
disappear completely, and they maintain a similar morphol-
ogy for many years (Fig. 3 and 4).
In this study differences in heart rate and intensity of
training could influence, at least partially, changes in alter-
ation repolarization between the first and later ECG. The
persistence of MRA in ECG tracer, despite a decrease in
training intensity, supports the lack of relation between the
ECG alteration and some specific type of training or sport.
Moreover, during the follow-up there was no abnormal loss
of fitness, and the progressive decrease in fitness was related
to the normal process of aging and subsequent decrease in
training intensity.
Athletes were followed from 4 to 20 years, and during
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this period there were no symptoms of heart disease in any
subject. We should emphasize that two of them (numbers 5
and 10) participated at the Olympic level. These athletes
continued in sports competition, and the results of this
study demonstrated no reason to limit either the competi-
tive activity or the intensity of physical activity.
In conclusion, despite the significant alterations found in
ECG at rest, the performance in the exercise test and the
results of echocardiography, myocardial perfusion and anti-
myosin studies, together with the lack of events during the
long-term follow-up, indicate that MRA have no patholog-
ical implications and should not, therefore, preclude phys-
ical training and competitive availability when a cardiac
pathology can be excluded. Thus, the presence of similar
ECG alterations must lead to a careful examination of the
athlete. The cause of MRA is unknown, and training is
likely the trigger. Further research is needed to determine
the origin.
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